Related Experiment Video
Updated: Jun 8, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Pharmacogenomics in pediatric leukemia.
Steven W Paugh1, Gabriele Stocco, William E Evans
1Hematological Malignancies Program and Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Current Opinion in Pediatrics
|September 24, 2010
Summary
Genetic variations influence how children respond to medications, particularly cancer drugs. Understanding these pharmacogenomic factors can help optimize treatment, improving efficacy and reducing toxicity in pediatric patients.
Area of Science:
- Genomics
- Pediatric Pharmacology
- Cancer Therapeutics
Background:
- Children often have a narrow therapeutic index for medications, increasing toxicity risk.
- Balancing drug toxicity and efficacy is crucial, especially in pediatric cancer chemotherapy.
- Interpatient variability in drug clearance affects treatment outcomes.
Purpose of the Study:
- To review genetic factors influencing drug pharmacokinetics and pharmacodynamics in children.
- To explore how genetic variations impact medication response in pediatric populations.
- To discuss the implications for optimizing childhood cancer treatment.
Main Methods:
- Review of genome-wide association studies in pediatric patient cohorts.
- Analysis of genetic variations affecting drug metabolism and response.
- Exploration of polygenic models for predicting drug response phenotypes.
Main Results:
- Genome-wide studies identify genetic variations impacting disease susceptibility and drug characteristics.
- Multiple genetic factors contribute to pharmacogenomic phenotypes and drug response.
- Findings offer insights into disease mechanisms and potential molecular diagnostics.
Conclusions:
- Advances in genomic technology are key to understanding interpatient drug response differences.
- Systematic deployment of genomics can enhance pediatric drug efficacy.
- Genomic insights promise to reduce drug toxicity in children.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...